Public-Health Impact of Delayed Access to Neoadjuvant-Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in Brazil

Clinical Breast Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles